PTPRC and acute myeloid leukemia: CD45 is an attractive target because it is expressed by most AML samples at relatively high levels (~200,000 receptors per cell), and the antigen does not internalize, which is important for 131I. Because CD45 is expressed on both normal and leukemic cells, it can be used to target the bone marrow.